We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Woodford Patient Capital Trust Plc | LSE:WPCT | London | Ordinary Share | GB00BVG1CF25 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 33.60 | 33.55 | 33.90 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMSUPP
RNS Number : 3990Q
Schroder UK Public Private Tst plc
26 February 2021
Schroder UK Public Private Trust plc
(the "Company")
Appointment of independent non-executive director
The Company is pleased to announce the appointment of Tim Edwards as an independent non-executive director of the Company, effective 26 February 2021. Mr Edwards will stand for election at the Company's next Annual General Meeting ("AGM") and if elected, will succeed Susan Searle as Chairman of the Company following her retirement once the AGM has concluded. Mr Edwards has also been appointed a member of the Audit, Risk and Valuation, Management Engagement and Nomination Committees.
Tim is a qualified chartered accountant with a widespread background in corporate finance and investment. He is currently the chairman of Storm Therapeutics Ltd, Karus Therapeutics Ltd and Modulus Oncology Ltd, a director of AstronauTx Ltd and an independent non-executive director of Record plc. Previously, Tim was a member of the governing board of InnovateUK, the UK's innovation agency, a director of the UK Cell and Gene Therapy Catapult and chairman of the UK BioIndustry Association.
At the date of this announcement , Mr Edwards holds no interests in the shares of the Company. I t is confirmed that there are no other details to be disclosed under FCA Listing Rule 9.6.13 R.
Susan Searle, on behalf of the Board, commented:
"The appointment of Tim is in line with the Board's agreed succession plans, as outlined in the Annual Report for the year ended 31 December 2019, and follows an extensive independent search over the last twelve months to find a candidate with the appropriate balance of skills and experience to complement those of the current Directors. My colleagues and I are delighted to welcome him to the Board and are very much looking forward to working with him."
Enquiries:
Gareth Faith
Schroder Investment Management Limited
020 7658 5264
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
BOAPPURAPUPGGCA
(END) Dow Jones Newswires
February 26, 2021 05:00 ET (10:00 GMT)
1 Year Woodford Patient Capital Chart |
1 Month Woodford Patient Capital Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions